Evidence map›Paper›PMID 31269957›Full record

ArticleJournal of translational medicine2019

Cathepsin L-induced galectin-1 may act as a proangiogenic factor in the metastasis of high-grade serous carcinoma.

Md Zahidul I Pranjol, Dmitry A Zinovkin, Annelie R T Maskell, Laura J Stephens, Sergey L Achinovich, Dmitry M Los', Eldar A Nadyrov, Michael Hannemann, Nicholas J Gutowski, Jacqueline L Whatmore

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Md Zahidul I PranjolInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, EX1 2LU, UK.
Dmitry A ZinovkinDepartment of Pathology, Gomel State Medical University, 246000, Gomel, Belarus.
Annelie R T MaskellInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, EX1 2LU, UK.
Laura J StephensInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, EX1 2LU, UK.
Sergey L AchinovichDepartment of Anatomical Pathology, Gomel Regional Clinical Oncological Dispensary, 246012, Gomel, Belarus.
Dmitry M Los'Gomel Regional Clinical Oncological Dispensary, 246012, Gomel, Belarus.
Eldar A NadyrovDepartment of Pathology, Gomel State Medical University, 246000, Gomel, Belarus.
Michael HannemannRoyal Devon and Exeter NHS Foundation Trust, Exeter, Devon, EX2 5DW, UK.
Nicholas J GutowskiInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, EX1 2LU, UK.
Jacqueline L WhatmoreInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, EX1 2LU, UK. J.L.Whatmore@exeter.ac.uk.ORCID 0000-0002-8753-1116
University of Exeter · GBGomel State Medical University · BYQueen Mary University of London · GBRoyal Devon & Exeter NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew treatment options for metastasised high-grade serous carcinoma (HGSC) are urgently needed. HGSC frequently metastasises to the omentum, inducing angiogenesis in the local omental microvasculature to facilitate tumour growth. We previously showed that HGSC-secreted cathepsin L (CathL) induces pro-angiogenic changes in disease relevant human omental microvascular endothelial cells (HOMECs), suggesting a role in tumour angiogenesis. Here we investigate whether CathL acts by inducing local production of the carbohydrate-binding protein galectin-1 (Gal1), which has been reported to be involved in tumourigenesis in other tumours.

methodsHOMECs were used for all experiments. Gal1 mRNA and protein levels were measured by RT-PCR and ELISA respectively. Gal1-induced cell proliferation was assessed using WST-1 assay, migration using a transwell assay and in vivo Gal1 expression by immunohistochemistry.

resultsCathL transcriptionally regulated HOMEC production and secretion of Gal1 via activation of NFκB (significantly inhibited by sulfasalazine). Gal1 significantly enhanced HOMEC migration (p < 0.001) and proliferation (p < 0.001), suggesting an autocrine action. The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 and PD98059 suggesting downstream activation of this pathway. Immunohistochemical analysis of omenta from HGSC patients with or without metastatic disease demonstrated a positive correlation between Gal1 expression and number of microvessels (r = 0.8702, p < 0.001), and area of vessels (r = 0.7283, p < 0.001), supporting a proangiogenic role for Gal1 in omental metastases.

conclusionHOMEC Gal1 transcription and release in response to CathL secreted from metastasising HGSC acts in an autocrine manner on the local microvasculature to induce pro-angiogenic changes, highlighting a potential new therapeutic target.

Indexed as

AdultCathepsin LCell MovementCell ProliferationEndothelial CellsExtracellular Signal-Regulated MAP KinasesFemaleGalectin 1Gene Expression Regulation, NeoplasticHumansMicrovesselsMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasms, Cystic, Mucinous, and SerousNeovascularization, PathologicCathepsin LExtracellular Signal-Regulated MAP KinasesGalectin 1NF-kappa BProto-Oncogene Proteins c-aktRNA, MessengerAngiogenesisGalectin-1High-grade serous carcinomaMetastasisSignalling pathways

Identifiers

PMID31269957
PMCPMC6610868
OpenAlexW2954054421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.